Clinical trial
Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
NCT00104130 · Bristol-Myers Squibb, Industry · Terminated
Key facts
| NCT number | NCT00104130 |
|---|---|
| Title | Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer |
| Official title | A Phase 2 Study of KOS-862 Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Hormone Resistant Prostate Cancer Who Have Progressed Following Initial Therapy for Metastatic Disease |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | KOS-862 |
| Enrollment | 53 |
| Start date | Dec 1, 2004 |
| Completion | Feb 1, 2005 |
| First posted | Feb 24, 2005 |
| Last update posted | Sep 17, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: